Floatz logo

Vinorelbine

Lung Carcinoma

National Cancer Institute (NCI)Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

39 Active assets in the Lung Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
M.D. Anderson Cancer Center
Phase 2B
Binimetinib
University of California, San Francisco
Phase 2B
Larotrectinib
National Cancer Institute (NCI)
Phase 2CCC
TRASTUZUMAB
National Cancer Institute (NCI)
Phase 2CCC
Tas-102
National Cancer Institute (NCI)
Phase 2CCC

View all 40 →

Same molecule, other indications

Vinorelbine is also rated in:

HER2 positive breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Recurrent Breast CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →